The Schizophrenia Pipeline: Emerging Mechanisms Beyond Dopamine

In "The Schizophrenia Pipeline: Emerging Mechanisms Beyond Dopamine," our experts turn to the next wave of mechanisms under investigation for schizophrenia.

Dr. Jackson asks Dr. Alva what emerging schizophrenia treatments excite him most. Dr. Alva calls the muscarinic pathway the field's clearest recent win, though not every muscarinic agent performs equally, and xanomeline-trospium chloride remains the only approved option in that class. He notes TAAR1 agonism, a mechanism outside classic D2 receptor binding, produced somewhat disappointing results, possibly confounded by high placebo response. He points to the glutamatergic pathway as another promising area under active investigation, alongside other agents with genuinely novel mechanisms. Dr. Alva stresses that continued discovery matters because schizophrenia still has no cure, and he sees a persistent lag in educating colleagues about why newer treatment options make clinical sense. Spencer Simon agrees, describing the current paradigm shift as a continuum, not a destination, with more innovation still to come that clinicians must actively track.

Dr. Jackson pivots to the glutamatergic system, noting its established role in depression and bipolar disorder, and asks what it might offer in schizophrenia. Dr. Hunter calls brilaroxazine a fascinating molecule and names inflammation and neuroplasticity as the defining psychiatric themes of 2026. He explains that inflammation runs rampant across serious mental illness, and brilaroxazine combines partial dopamine D2, D3, and D4 agonism with modest serotonin 1A and 2A activity, plus an anti-inflammatory effect through 5-HT6 receptors that appears linked to cognitive improvement. Trials have shown reductions in circulating inflammatory cytokines as the compound advances through phase three testing. Dr. Hunter argues that any agent attacking inflammation at its root could meaningfully improve long-term prognosis, particularly for negative and cognitive symptoms, which he believes are disproportionately driven by inflammatory processes. Dr. Hicks closes succinctly: there is no room left for clinical inertia.

In "Empowering Functional Recovery: Setting Goals in Schizophrenia Care," the panel will confront how low the field's expectations for functional recovery have become.